Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Baylor College of Medicine
SWOG Cancer Research Network
Centre Leon Berard
Novartis
Obafemi Awolowo University
OHSU Knight Cancer Institute
Medical College of Wisconsin
Dana-Farber Cancer Institute
University of Liverpool
University of Jena
Ascentage Pharma Group Inc.
Australasian Leukaemia and Lymphoma Group
University of Auckland, New Zealand
Bristol-Myers Squibb
Rennes University Hospital
Medical College of Wisconsin
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
University of Washington
Gruppo Italiano Malattie EMatologiche dell'Adulto
Institut Bergonié
Novartis
Novartis
Novartis
Mansoura University
Cardiff University
National Research Center for Hematology, Russia
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
University of Washington
Emory University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Norwegian University of Science and Technology
The University of Hong Kong
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Novartis
Dana-Farber Cancer Institute
Novartis
M.D. Anderson Cancer Center
Tongji Hospital
Bristol-Myers Squibb
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute